• To use advanced imaging technologies of atherosclerosis in the coronary and carotid arteries together with information obtained by proteomics/metabolomics/genomics technologies to improve risk prediction for cardiovascular disease. The clinical implications would be better-targeted intensive risk factor interventions, which will save both lives and medical costs.
• To improve the understanding of underlying mechanisms of disease in CVD and COPD. An example is use of detailed metabolic imaging with computed tomography (CT) to elucidate the links between fat deposition patterns and risk of subclinical atherosclerosis and development of CVD in persons with and without COPD. This could lead to the discovery of new treatment targets and preventive strategies.
• To improve the understanding of the epidemiology of CVD and COPD. An example is investigating why high morbidity and mortality rates from CVD and COPD persist in individuals with low socioeconomic status, despite an overall reduction in mortality from CVD and a leveling of age-adjusted mortality for COPD. This could lead to an improved care of COPD patients to prevent CVD, and better-targeted intervention in persons with a low socioeconomic status.
• To evaluate the cost-effectiveness of usingnew imaging techniques and modern -omics technologies to target preventive efforts against CVD and COPD.